Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Posted on by

-Sapience to present data across its pipeline, including non-clinical immunotherapy results on ST316 and ST101 and preclinical results on its novel AP-1 complex antagonist TARRYTOWN, N.Y., March 5, 2024 /PRNewswire/ — Sapience Therapeutics, Inc., a clinical-stage biotechnology company…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.